Get started
Author

Chiara Saladino

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer
2020 · Sheelagh Frame, Chiara Saladino, et al. · PLoS ONE · 94
PDF
ATM is Activated by Default in Mitosis, Localizes at Centrosomes and Monitors Mitotic Spindle Integrity
2005 · Elisa Oricchio, Chiara Saladino, et al. · Cell Cycle · 69
PDF
C-NAP1 and rootletin restrain DNA damage-induced centriole splitting and facilitate ciliogenesis
2012 · Pauline C. Conroy, Chiara Saladino, et al. · Cell Cycle · 51
PDF
Centriole separation in DNA damage‐induced centrosome amplification
2009 · Chiara Saladino, Emer Bourke, et al. · Environmental and Molecular Mutagenesis · 39
Centrosomes, DNA Damage and Aneuploidy
2012 · Chiara Saladino, Emer Bourke, et al. · Humana Press eBooks · 10
CYC065, potential therapeutic agent for AML and MLL leukaemia
2015 · Sheelagh Frame, Chiara Saladino, et al. · Clinical Lymphoma Myeloma & Leukemia · 6
Abstract LB-202: Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors.
2013 · Geoffrey I. Shapiro, John Hilton, et al. · Cancer Research · 6
Abstract 1650: CYC065, a novel CDK2/5/9 inhibitor: detailed mechanistic studies, determinants of sensitivity and synergistic combinations
2015 · Chiara Saladino, Sheelagh Frame, et al. · Cancer Research · 4
Abstract 222: Novel protein drug conjugates targeting ROR1 through the development and exploitation of a drug discovery platform based on small, engineered VNAR domains
2019 · Graham Cotton, Jennifer Thom, et al. · Cancer Research · 3
Abstract 4178: The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations
2017 · Sylvie Moureau, Craig MacKay, et al. · Cancer Research · 3
Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia
2016 · S. Moureau, E. Pohler, et al. · European Journal of Cancer · 3
Abstract B182: Molecular basis for clinical development of the novel CDK2/9 inhibitor CYC065 in oncology
2015 · Craig MacKay, Sheelagh Frame, et al. · Molecular Cancer Therapeutics · 3
Abstract LB045: Exploiting biparatopic binding to deliver novel, differentiated ALPP/ALPPL2 targeting protein drug conjugates
2024 · Graham Cotton, Estelle G. McLean, et al. · Cancer Research · 2
Abstract 538: Exploiting the properties of VNAR domains for the development of novel efficacious protein drug conjugates targeting the oncofetal protein ROR1
2020 · Graham Cotton, Jennifer Thom, et al. · Cancer Research · 2
Abstract LB229: ALM-401: A first-in-class next generation bispecific ADC configured to deliver superior efficacy in selected solid tumor indications
2025 · Graham Cotton, Chiara Saladino, et al. · Cancer Research · 1
TSY-310, a novel bispecific EGFR×ROR1 ADC: Assessment of antitumor activity in heterogeneous breast tumors through enhanced internalization and bystander cytotoxicity.
2026 · Kuo-Ming Yu, Erick Co, et al. · Journal of Clinical Oncology
Abstract 1684: ALM-502: A highly effective ADC for solid tumor therapy - enhancing payload delivery through molecular design
2026 · Graham Cotton, Estelle McLean, et al. · Cancer Research
Abstract LB041: Exploiting a multi-center pre-clinical mouse PDX mini trial to identify new clinical opportunities for protein-drug conjugates (PDCs) targeting ROR1
2024 · Aaron N. Cranston, Mark Wappett, et al. · Cancer Research
Abstract LB011: Development of novel protein drug conjugates (PDCs) for the selective targeting of ALPP/ALPPL2 expressing tumors
2023 · Graham Cotton, Paul Trumper, et al. · Cancer Research
Abstract LB096: Development of a next generation ROR1 targeting Protein Drug Conjugate (PDC)
2021 · Graham Cotton, Jennifer Thom, et al. · Cancer Research
Abstract 222: Novel protein drug conjugates targeting ROR1 through the development and exploitation of a drug discovery platform based on small, engineered VNAR domains
2019 · Graham Cotton, Jennifer Thom, et al. · Experimental and Molecular Therapeutics
Molecular Rationale for Clinical Development of CYC065 in Hematology
2015 · Daniella Zheleva, Sheelagh Frame, et al. · Clinical Lymphoma Myeloma & Leukemia
Reply to Letter to the Editor
2006 · Elisa Oricchio, Chiara Saladino, et al. · Cell Cycle
PDF
Works count: 24
Citation count: 296
H-index: 6
I10-index: 5
Year
Topic
Type